Brozena Sj
University of South Florida
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Brozena Sj.
Plastic and Reconstructive Surgery | 1994
Wells Ke; Cruse Cw; Baker Jl; Daniels Sm; Robert A. Stern; Newman C; Seleznick Mj; Vasey Fb; Brozena Sj; Sharon E. Albers
A retrospective study was performed to determine the frequency of new symptoms and diseases after silicone breast implantation. Questionnaires were mailed to 826 women who made up a breast implant group (n = 516) and a control group who had undergone blepharoplasty (n = 124), liposuction (n = 111), or rhinoplasty (n = 75). Responses were obtained from 370 women (45 percent); however, 68 of these patients (18 percent) were considered ineligible. The overall response rate was 59 percent for the breast implant group and 46 percent for controls. The 302 eligible women included patients with silicone breast implants (n = 222) and controls (n = 80). Women with implants were significantly younger than controls, the median age of women with breast implants being 37 years compared with 46.5 years for controls (p < 0.0001). We compared the incidence of 23 symptoms and 4 connective-tissue diseases after cosmetic surgery in the two groups. The symptoms of swollen glands under arms (p < 0.05) and tender glands under arms (p < 0.01) were statistically more frequent in the breast implant group. The symptom change in skin color was more common in the controls (p < 0.001). The Bonferroni correction for multiple (27) endpoints adjusts the 5 and 1 percent significance cutoff points to 0.00185 and 0.00037, respectively, leaving only change of skin color significant at the 5 percent level on the adjusted data. No cases of scleroderma or lupus were found, and the incidence of arthritis was not significantly different between the implant and control groups. (Plast. Reconstr. Surg. 93: 907, 1994.)
Journal of The American Academy of Dermatology | 1992
Sharon E. Albers; Brozena Sj; L. Frank Glass; Neil A. Fenske
Alkaptonuria is a rare genetic disorder in which the enzyme homogentisic acid oxidase is deficient, resulting in the accumulation of homogentisic acid in various bodily tissues. This is a multisystem disorder with a characteristic blue-black discoloration of the skin and cartilage, which is termed ochronosis. Herein we report a profound case of ochronosis secondary to alkaptonuria. Furthermore, we review the clinical manifestations of alkaptonuria and discuss the spectrum of ochronosis, both endogenous and exogenous.
Surgical Oncology-oxford | 1992
Douglas S. Reintgen; Cruse Cw; Wells Ke; Stankard Ce; Hussain I. Saba; K. Schroer; Charles E. Cox; Claudia Berman; Frank Glass; L. Alvarez; Brozena Sj; Neil A. Fenske; P.J. Fabri
The 5-year survival rate for malignant melanoma has increased 40% over the last 50 years. During this same time period, the treatment for the disease has not changed significantly, and consists of wide excision of the primary tumour and perhaps regional node dissection. The purpose of this study was to investigate the possible impact of screening/education programs on melanoma survival. In 1987, a multimodality University-based Melanoma Treatment Center was established and programs were instituted for skin cancer screening and Continuing Medical Education (CME) of health care providers. During the last 5 years, 594 patients with newly diagnosed melanoma have been registered at the clinic. The number of patients with localized (stage 1 or 2, negative regional nodes) disease was 516 (85%). For all stages of disease, the 3-year actuarial survival for this screened population was 85%. From the National Cancer Database of 9879 patients registered with melanoma for 1988, 75% had localized disease and the 3-year survival was 76%. There were significant differences noted between the screened Florida population and the nationwide database using an odds ratio statistic. This involved a higher frequency of patients diagnosed with localized disease (odds ratio = 1.89 (1.49-2.40)) and a better survival (odds ratio = 1.79 (1.41-2.27)) in the screened population served by CME-educated community physicians.
Archives of Dermatology | 1988
Brozena Sj; Neil A. Fenske; C. Wayne Cruse; Carmen G. Espinoza; Frank B. Vasey; Bernard F. Germain; Luis R. Espinoza
Seminars in Surgical Oncology | 1993
Brozena Sj; Neil A. Fenske; Perez Ir
Cutis | 1988
Brozena Sj; Laura E. Cohen; Neil A. Fenske
Geriatrics | 1993
Haag Ml; Brozena Sj; Neil A. Fenske
Cutis | 1993
Sharon E. Albers; Brozena Sj; Neil A. Fenske
Cutis | 1993
Lynn A; Brozena Sj; Carmen G. Espinoza; Neil A. Fenske
Archives of Dermatology | 1991
Frank B. Vasey; Luis R. Espinoza; Píndaro Martínez-Osuna; Mitchel J. Seleznick; Brozena Sj; Neil A. Penske